These alterations, as well as their synthetic lethal relationships with SWI/SNF and non-SWI/SNF proteins, may be pharmacologically exploited for the treatment of diverse hematological cancers. This evidence concerns the gene SMARCA1 and hematopoietic and lymphoid cell neoplasm.